Affibody to publish data on therapeutic effects of Affibody molecules in a cancer model
In the study the potential therapeutic product completely prevented tumor formation from xenografts derived from the cell line SKOV-3, representing an aggressive tumor model with high HER2-expression. The radio-labeled Affibody® molecules also showed therapeutic efficacy in a tumor model with modest HER2-expression.
Dr Lars Abrahmsén, Chief Scientific Officer at Affibody AB, commented: "These results confirm that Affibody® molecules armed with a low-energy beta emitter may be therapeutic candidates for targeted treatment of disseminated tumors with HER2 expression. Together with other promising data, this encourages the company to proceed with its development of targeted therapeutics. The in vivo association to serum albumin increases the half-life of the Affibody® molecule, thereby optimizing the amount of drug loaded onto the tumor. The albumin-binding technology should be applicable to any small protein or peptide drug to increase their plasma circulation time."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.